Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KROS

Keros Therapeutics Inc

Apr 28 • 04:00PM ET

11.37

+0.36 3.27 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: SRPT VRTX ALNY IONS ARWR TVRD BLUE RGNX MCRB PBYI

| Held by: IWM VTI IWN VXF BSVO VTWO IBB SCHA AVUV DFAS

Scroll to Statements

Index	RUT	P/E	6.24	EPS (ttm)	1.82	Insider Own	8.71%	Shs Outstand	19.54M	Perf Week	0.53%
Market Cap	224.19M	Forward P/E	-	EPS next Y	-5.75	Insider Trans	-1.00%	Shs Float	18.00M	Perf Month	7.16%
Enterprise Value	-46.35M	PEG	-	EPS next Q	-1.09	Inst Own	98.02%	Short Float	7.78%	Perf Quarter	-37.87%
Income	87.01M	P/S	0.92	EPS this Y	-332.28%	Inst Trans	-52.06%	Short Ratio	3.42	Perf Half Y	-24.40%
Sales	244.06M	P/B	0.73	EPS next Y	-7.67%	ROA	18.15%	Short Interest	1.40M	Perf YTD	-44.16%
Book/sh	15.51	P/C	0.78	EPS next 5Y	-	ROE	19.90%	52W High	22.55 -49.58%	Perf Year	-20.27%
Cash/sh	14.58	P/FCF	2.12	EPS past 3/5Y	- -	ROIC	27.40%	52W Low	10.41 9.17%	Perf 3Y	-74.37%
Dividend Est.	-	EV/EBITDA	-0.67	Sales past 3/5Y	- -	Gross Margin	99.38%	Volatility	3.18% 4.23%	Perf 5Y	-83.24%
Dividend TTM	-	EV/Sales	-0.19	EPS Y/Y TTM	137.16%	Oper. Margin	27.72%	ATR (14)	0.49	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.45	Sales Y/Y TTM	6774.96%	Profit Margin	35.65%	RSI (14)	44.50	Recom	1.75
Dividend Gr. 3/5Y	- -	Current Ratio	15.45	EPS Q/Q	24.40%	SMA20	-2.30%	Beta	0.95	Target Price	23.00
Payout	0.00%	Debt/Eq	0.06	Sales Q/Q	-87.34%	SMA50	-7.64%	Rel Volume	0.66	Prev Close	11.01
Employees	78	LT Debt/Eq	0.05	Earnings	Mar 04 AMC	SMA200	-27.14%	Avg Volume	408.99K	Price	11.37
IPO	Apr 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-23.37% -89.50%	Trades		Volume	269,375	Change	3.27%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$26
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral	$18
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral	$15
Dec-16-24	Reiterated	Oppenheimer	Outperform	$102 → $63
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-13-24	Reiterated	H.C. Wainwright	Buy	$100 → $47
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy	$96
Jun-25-24	Initiated	Oppenheimer	Outperform	$102
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight	$60
Jul-31-23	Initiated	Wedbush	Outperform	$86
Jul-26-23	Initiated	BofA Securities	Buy	$65
Feb-14-23	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-09-26 08:00AM	Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
08:00AM	Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS (GlobeNewswire)
Mar-06-26 11:57AM	Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
Mar-05-26 12:53PM	Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? (Zacks) -14.96%
Mar-04-26 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-28-26 12:35PM	Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference (MarketBeat)
Feb-26-26 04:01PM	Keros Therapeutics Appoints Charles Newton to its Board of Directors (GlobeNewswire) -5.59%
Feb-18-26 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-03-26 11:39AM	Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results? (Zacks)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-26-26 09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
11:55AM	Loading…
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks)
Jan-02-26 12:41PM	This Health Name Gains Over 400% In 2025. A Gold Stock Is Right Behind It. (Investor's Business Daily) -8.94%
04:32AM	Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics (Zacks)
Dec-31-25 07:33AM	5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close (Zacks)
11:40AM	Loading…
Dec-30-25 11:40AM	KROS or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Dec-22-25 12:00PM	Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why (Zacks) +5.33%
09:55AM	Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
04:02AM	Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros (Zacks)
Dec-15-25 09:14AM	Buy These 5 Best Value Stocks to Boost Your Portfolio in December (Zacks)
Dec-12-25 12:00PM	What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? (Zacks)
11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Nov-28-25 09:53AM	Buy These 5 Best Value Stocks to Make the Most of P/B Ratio (Zacks)
Nov-26-25 11:40AM	KROS or NVZMY: Which Is the Better Value Stock Right Now? (Zacks)
09:55AM	How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% (Zacks)
Nov-20-25 04:01PM	Keros Therapeutics Announces Final Results of Tender Offer (GlobeNewswire)
Nov-19-25 06:00AM	Keros Therapeutics Announces Preliminary Results of Tender Offer (GlobeNewswire)
Nov-13-25 07:34AM	5 Undervalued Stocks That Are Poised for Growth in November (Zacks)
Nov-10-25 11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks) +5.19%
09:55AM	Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? (Zacks)
Nov-05-25 05:40PM	Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-21-25 09:43AM	Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Oct-20-25 06:00AM	Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares (GlobeNewswire) +9.83%
Oct-15-25 06:30AM	Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital (GlobeNewswire)
Sep-08-25 08:00AM	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting (GlobeNewswire)
Aug-28-25 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-21-25 08:30AM	ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment (PR Newswire) +6.61%
06:56AM	Keros gains FDA orphan drug status for DMD treatment KER-065 (Pharmaceutical Technology)
Aug-20-25 09:48AM	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-06-25 05:45PM	Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.29%
04:15PM	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 (GlobeNewswire)
04:01PM	Keros Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 11:40AM	KROS vs. EXAS: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-23-25 10:54AM	Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? (Zacks) +5.10%
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks)
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept (GlobeNewswire)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
Jun-11-25 09:40AM	McDonalds downgraded on GLP-1 drug worries: Wall Streets top analyst calls (TipRanks)
Jun-10-25 02:37PM	Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst (Benzinga)
Jun-09-25 03:12PM	ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal (PR Newswire) -6.32%
06:55AM	Keros Announces Return of $375 Million in Excess Capital to Stockholders (GlobeNewswire)
Jun-06-25 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 11:24PM	Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial (Insider Monkey)
12:54PM	Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% (Benzinga)
06:55AM	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring (GlobeNewswire)
May-27-25 01:45PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees (GlobeNewswire)
May-21-25 08:00AM	ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
May-19-25 08:00AM	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value (GlobeNewswire)
May-12-25 12:11PM	ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
08:00AM	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:31PM	Keros Reinforces Commitment to Maximizing Stockholder Value (GlobeNewswire)
02:10PM	ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders (PR Newswire)
May-06-25 07:10PM	Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates (Zacks) -5.46%
04:01PM	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-25 08:40AM	Implied Volatility Surging for Keros Therapeutics Stock Options (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
12:05PM	Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz (TipRanks)
11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 12:58PM	Keros Therapeutics considers sale amid investor pressure (Pharmaceutical Technology) +18.49%
06:00AM	Keros Therapeutics Announces Review of Strategic Alternatives (GlobeNewswire)
Mar-31-25 06:00AM	Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers (GlobeNewswire) -5.56%
Mar-21-25 09:55AM	Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet (Zacks)
Mar-05-25 09:55AM	Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade (Zacks)
Feb-28-25 05:00PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Feb-26-25 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-30-25 08:00AM	Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:53AM	Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-21-25 08:00AM	Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire) +5.06%

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Director	Apr 15 '26	Buy	11.70	1,000	11,700	8,450	Apr 17 04:15 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Option Exercise	0.30	55,000	16,500	440,708	Apr 06 04:15 PM
OrbiMed Genesis Master Fund, L	Shareholder	Mar 31 '26	Proposed Sale	11.04	45,057	497,429		Mar 31 09:57 PM
BIENAIME JEAN JACQUES	Director	Mar 09 '26	Buy	11.21	2,000	22,420	7,450	Mar 11 04:33 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Feb 19 '26	Sale	16.17	7,015	113,433	385,708	Feb 20 04:15 PM
Lerner Lorena Raquel	Chief Science Officer	Feb 18 '26	Sale	16.35	3,873	63,324	31,127	Feb 20 04:15 PM
Cho Esther	SVP, General Counsel	Feb 18 '26	Sale	16.35	4,745	77,581	39,755	Feb 20 04:15 PM
Regnante Keith	CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	16.35	4,739	77,483	39,261	Feb 20 04:15 PM
Pontifax Management 4 G.P. (20	10% Owner	Oct 15 '25	Sale	17.75	4,787,331	84,975,125	0	Oct 17 05:53 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 15 '25	Sale	17.75	5,389,264	95,659,436	0	Oct 15 01:24 PM
Rovaldi Christopher	Affiliate	Sep 12 '25	Proposed Sale	15.71	85,306	1,340,157		Sep 12 04:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KROS

Keros Therapeutics Inc

Upgrade your Finviz experience